Researchers are scheduled to present Phase I data relating to Semafore Pharmaceuticals’ lead product candidate, SF1126, as a treatment for patients with relapsed and refractory myeloma during the 51st American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2009, at the Ernst N. Morial Convention Center in New Orleans, LA.
Poster details are as follows:
Presentation 3879: Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma
Monday, Dec. 7, 2009, 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)
Poster Board III-815
Conclusions: The PI3K inhibitor SF1126 resulted in similar pharmacokinetics (PK) to that seen in solid tumor patients and in vivo studies demonstrated that PI3K activity in the plasma cell compartment of the bone marrow had suppression of this key pathway following SF1126. Completion of the study at the current dose (1110mg/m2) and planning for a future trial combining SF1126 with other active agents in myeloma is currently ongoing. Additional PK/pharmacodynamic and clinical data from this trial will be available.
A copy of the abstract is now available on ASH's website at http://www.hematology.org or Semafore’s website at http://www.semaforepharma.com/publications.html.
GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes